Evidence map›Paper›PMID 38147070›Full record

ArticleOncotarget2023

One more step toward treatment of PARP inhibitor-resistant ovarian cancers.

Upasana Ray, Prabhu Thirusangu, Viji Shridhar

Abstract readEditorial
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Upasana Ray
Prabhu Thirusangu
Viji Shridhar

Funding

Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
PG545 synergizes with PARP inhibitors in ovarian cancer to disrupt DNA repair through modulation of DEK-RAD51 axisR21CA263003 · NCI · MAYO CLINIC ROCHESTER · PI SHRIDHAR, VIJI · 2022 to 2023
$404k
NCI NIH HHS P50 CA136393NCI NIH HHS R21 CA263003
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsOvarian NeoplasmsFemaleHumansPoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitorscell deathDNA damageovarian cancerPARP inhibitorsPG545

Identifiers

PMID38147070
PMCPMC10750833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.